# EDGAR Filing Document

**Accession Number:** 0001892322
**File Stem:** 0001493152-26-023382
**Filing Date:** 2026-5
**Character Count:** 131708
**Document Hash:** 20799a0de7a1bc549ead1d00b59a430a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-023382.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001493152-26-023382

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 91

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HeartCore Enterprises, Inc.
- **CENTRAL INDEX KEY:** 0001892322
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 870913420
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41272
- **FILM NUMBER:** 26982613

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1-2-33, HIGASHIGOTANDA,
- **STREET 2:** SHINAGAWA-KU
- **CITY:** TOKYO
- **PROVINCE COUNTRY:** M0
- **ZIP:** 150-0031
- **BUSINESS PHONE:** 650-695-2583

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 14F, SHIBUYA SAKURA STAGE CENTRAL BLDG.,
- **STREET 2:** 1-2 SAKURAGAOKA-CHO, SHIBUYA-KU,
- **CITY:** TOKYO
- **PROVINCE COUNTRY:** M0
- **ZIP:** 150-0031

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ______, 20___, to _____, 20___.**

**Commission File Number 001-41272**

**HeartCore Enterprises, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

| | |
|:---|:---|
| **Delaware** | **87-0913420** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (I.R.S. Employer<br> Identification Number) |

---

**1-2-33, Higashigotanda, Shinagawa-ku**

**Tokyo, Japan 141-0022**

(Address of Principal Executive Offices) (Zip Code)

**<u>+81-3-6409-6966</u>**

(Registrant's Telephone Number, Including Area Code)

**<u>N/A</u>**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each Exchange on which Registered** |
| Common Stock | HTCR | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 15, 2026, there were 1,441,565 shares of outstanding common stock of the registrant.

**HeartCore Enterprises, Inc.**

**Contents**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **[PART I - FINANCIAL INFORMATION](#sa_001)** | **[PART I - FINANCIAL INFORMATION](#sa_001)** |  |
| Item 1. | [Financial Statements](#sa_002) | F-1 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#sa_003) | 1 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#sa_004) | 6 |
| Item 4. | [Controls and Procedures](#sa_005) | 6 |
| **[PART II - OTHER INFORMATION](#sa_006)** | **[PART II - OTHER INFORMATION](#sa_006)** |  |
| Item 1. | [Legal Proceedings](#sa_007) | 7 |
| Item 1A. | [Risk Factors](#sa_008) | 7 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#sa_009) | 7 |
| Item 3. | [Defaults Upon Senior Securities](#sa_010) | 7 |
| Item 4. | [Mine Safety Disclosures](#sa_011) | 7 |
| Item 5. | [Other Information](#sa_012) | 7 |
| Item 6. | [Exhibits](#sa_013) | 7 |
| **[Signatures](#sa_014)** | **[Signatures](#sa_014)** | 8 |

---

i

**PART I - FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**HEARTCORE ENTERPRISES, INC.**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
|  | **(Unaudited)** |  |
| **ASSETS** |  |  |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $774033 | $1985962 |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 572547 | 707865 |
| &nbsp;&nbsp;&nbsp;Investments in marketable securities | 3394190 | 3690187 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 222818 | 182077 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term note receivable | 100000 | 100000 |
| &nbsp;&nbsp;&nbsp;Deferred offering costs | 250000 | 250000 |
| &nbsp;&nbsp;&nbsp;Other current assets | 175335 | 208503 |
| &nbsp;&nbsp;&nbsp;Proceeds receivable from sale of discontinued operations | 1382897 | 1291298 |
| **Total current assets** | **6871820** | **8415892** |
| **Non-current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 279185 | 291589 |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 506456 | 29449 |
| &nbsp;&nbsp;&nbsp;Long-term investment in warrants | 273859 | 280924 |
| &nbsp;&nbsp;&nbsp;Deferred tax assets | 22633 | 23121 |
| &nbsp;&nbsp;&nbsp;Security deposits | 278154 | 282958 |
| &nbsp;&nbsp;&nbsp;Other non-current assets | 241 | 549 |
| &nbsp;&nbsp;&nbsp;Long-term proceeds receivable from sale of discontinued operations | 3539421 | 3736995 |
| **Total non-current assets** | **4899949** | **4645585** |
| **Total assets** | $**11771769** | $**13061477** |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $1230686 | $1146501 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses – related party | 96333 | 124618 |
| &nbsp;&nbsp;&nbsp;Accrued payroll and other employee costs | 663683 | 509547 |
| &nbsp;&nbsp;&nbsp;Due to related party | 401 | 285 |
| &nbsp;&nbsp;&nbsp;Short-term debt – related party | 69000 | 75000 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debts | 51697 | 50598 |
| &nbsp;&nbsp;&nbsp;Insurance premium financing | 97773 | 13430 |
| &nbsp;&nbsp;&nbsp;Factoring liability | 124508 | 135982 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, current | 308119 | 32793 |
| &nbsp;&nbsp;&nbsp;Income tax payables | 1847411 | 1857386 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 650469 | 676216 |
| &nbsp;&nbsp;&nbsp;Derivative liability | 122589 | 121719 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 598602 | 586175 |
| **Total current liabilities** | **5861271** | **5330250** |
| **Non-current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Long-term debts | 434895 | 448376 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, non-current | 211544 | - |
| **Total non-current liabilities** | **646439** | **448376** |
| **Total liabilities** | **6507710** | **5778626** |
| **Shareholders' equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Preferred shares, $0.0001 par value, 20,000,000 shares authorized; Series A convertible preferred shares, 4,000 shares designated, 1,017 shares issued and outstanding as of March 31, 2026 and December 31, 2025; aggregate liquidation preference of $1,262,686 and $1,158,362 as of March 31, 2026 and December 31, 2025, respectively | 691858 | 691858 |
| &nbsp;&nbsp;&nbsp;Common shares, $0.0001 par value, 200,000,000 shares authorized, 1,288,812 and 1,270,991 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively\* | 129 | 127 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 21876230 | 21902169 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (15627241) | (13755534) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (66099) | (58497) |
| **Total HeartCore Enterprises, Inc. shareholders' equity** | **6874877** | **8780123** |
| &nbsp;&nbsp;&nbsp;Non-controlling interests | (1610818) | (1497272) |
| **Total shareholders' equity** | **5264059** | **7282851** |
| **Total liabilities and shareholders' equity** | $**11771769** | $**13061477** |

---

\* On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company's issued and outstanding common shares. References to share and per share information of common shares in the unaudited consolidated financial statements have been retroactively adjusted. See NOTE 14.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**HEARTCORE ENTERPRISES, INC.**

**UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months** | **For the Three Months** |
|  | **Ended March 31,** | **Ended March 31,** |
|  | **2026** | **2025** |
| Revenues | $1245844 | $2093413 |
| Cost of revenues (including cost of revenues resulting from transactions with a related party of $114,535 and $25,195 for the three months ended March 31, 2026 and 2025, respectively) | 1171799 | 1549639 |
| **Gross profit** | **74045** | **543774** |
| **Operating expenses:** |  |  |
| Selling expenses | 42812 | 152922 |
| General and administrative expenses (including general and administrative expenses resulting from transactions with a related party of nil and $17,615 for the three months ended March 31, 2026 and 2025, respectively) | 1571734 | 1581205 |
| **Total operating expenses** | **1614546** | **1734127** |
| **Loss from continuing operations** | **(1540501)** | **(1190353)** |
| **Other income (expenses):** |  |  |
| Changes in fair value of investments in marketable securities | (295997) | (1781664) |
| Changes in fair value of investment in warrants | (7065) | (51621) |
| Changes in fair value of derivative liability | (870) |  |
| Interest income | 582 | 2243 |
| Interest expenses | (16625) | (17794) |
| Other income | 14095 | 9313 |
| Other expenses | (112865) | (547) |
| **Total other expenses** | **(418745)** | **(1840070)** |
| **Loss from continuing operations before income tax expense** | **(1959246)** | **(3030423)** |
| Income tax expense | 17469 | 39608 |
| **Net loss from continuing operations** | **(1976715)** | **(3070031)** |
| **Loss from discontinued operations, net of income tax** | **-** | **(67350)** |
| **Net loss** | **(1976715)** | **(3137381)** |
| Less: net loss attributable to non-controlling interests | (105008) | (50389) |
| **Net loss attributable to HeartCore Enterprises, Inc.** | **(1871707)** | **(3086992)** |
| Dividends accrued on Series A convertible preferred shares | (27968) | - |
| **Net loss attributable to HeartCore Enterprises, Inc. common shareholders** | $**(1899675)** | $**(3086992)** |
| **Other comprehensive loss:** |  |  |
| Foreign currency translation adjustment | (16140) | (8014) |
| **Total comprehensive loss** | **(1992855)** | **(3145395)** |
| Less: comprehensive loss attributable to non-controlling interests | (113546) | (49152) |
| **Comprehensive loss attributable to HeartCore Enterprises, Inc.** | $**(1879309)** | $**(3096243)** |
| **Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share\*** |  |  |
| Basic | $(1.49) | $(2.74) |
| Diluted | $(1.49) | $(2.74) |
| **Loss from discontinued operations per common share\*** |  |  |
| Basic | $- | $(0.06) |
| Diluted | $- | $(0.06) |
| **Net loss attributable to HeartCore Enterprises, Inc. per common share\*** |  |  |
| Basic | $(1.49) | $(2.80) |
| Diluted | $(1.49) | $(2.80) |
| **Weighted average common shares outstanding\*** |  |  |
| Basic | 1271631 | 1102702 |
| Diluted | 1271631 | 1102702 |

---

\* On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company's issued and outstanding common shares. References to share and per share information of common shares in the unaudited consolidated financial statements have been retroactively adjusted. See NOTE 14.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**HEARTCORE ENTERPRISES, INC.**

**UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY**

**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Shares** | **Common Shares** | | | | | | | |
|  | **Number of**<br>**Shares\*** |<br>**Amount** |<br>**Subscription**<br>**Receivable** | **Additional**<br> **Paid-in**<br> **Capital** |<br>**Accumulated**<br>**Deficit** | **Accumulated<br> Other**<br> **Comprehensive**<br>**Income** | **Total<br> HeartCore Enterprises, Inc.**<br> **Shareholders'**<br>**Equity** |<br>**Non-controlling**<br>**Interests** | **Total**<br>**<br> Shareholders'**<br>**Equity** |
| **Balance, January 1, 2025** | **1096900** | $**110** | $**(103942)** | $**20658236** | $**(16244843)** | $**343936** | $**4653497** | $**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1191482)** | $**3462015** |
| Net loss |  |  |  |  | (3086992) |  | (3086992) | (50389) | (3137381) |
| Foreign currency translation adjustment |  |  |  |  |  | (9251) | (9251) | 1237 | (8014) |
| Issuance of common shares related to at the market offering agreement | 794 |  |  | 30445 |  |  | 30445 |  | 30445 |
| Collection of subscription receivable |  |  | 103942 |  |  |  | 103942 |  | 103942 |
| Exercise of stock options | 5000 | 1 |  | 116999 |  |  | 117000 |  | 117000 |
| Stock-based compensation | 1073 | - | - | 32280 | - | - | 32280 | - | 32280 |
| **Balance, March 31, 2025** | **1103767** | $**111** | $**-** | $**20837960** | $**(19331835)** | $**334685** | $**1840921** | $**(1240634)** | $**600287** |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Shares** | **Preferred Shares** | **Common Shares** | **Common Shares** | | | | | | |
|  | **Number of**<br>**Shares** |<br>**Amount** | **Number of**<br>**Shares\*** |<br>**Amount** | **Additional**<br> **Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Accumulated<br> Other**<br> **Comprehensive**<br>**Loss** | **Total<br> HeartCore<br> Enterprises, Inc.**<br> **Shareholders'**<br>**Equity** |<br>**Non-controlling**<br>**Interests** | **Total**<br> **Shareholders'**<br>**Equity** |
| **Balance, January 1, 2026** | **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1017** | $**691858** | **1270991** | $**127** | $**21902169** | $**(13755534)** | $**(58497)** | $**8780123** | $**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1497272)** | $**7282851** |
| Net loss |  |  |  |  |  | (1871707) |  | (1871707) | (105008) | (1976715) |
| Foreign currency translation adjustment |  |  |  |  |  |  | (7602) | (7602) | (8538) | (16140) |
| Dividends accrued on Series A convertible preferred shares |  |  |  |  | (27968) |  |  | (27968) |  | (27968) |
| Stock-based compensation |  |  | 796 |  | 2031 |  |  | 2031 |  | 2031 |
| Reverse stock split rounding adjustment | - | - | 17025 | 2 | (2) | - | - | - | - | - |
| **Balance, March 31, 2026** | **1017** | $**691858** | **1288812** | $**129** | $**21876230** | $**(15627241)** | $**(66099)** | $**6874877** | $**(1610818)** | $**5264059** |

---

\* On April 2, 2026, the Company effected a 1-for-20 reverse stock split of the Company's issued and outstanding common shares. References to share and per share information of common shares in the unaudited consolidated financial statements have been retroactively adjusted. See NOTE 14.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**HEARTCORE ENTERPRISES, INC.**

**UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months** | **For the Three Months** |
|  | **Ended March 31,** | **Ended March 31,** |
|  | **2026** | **2025** |
| **Cash flows from operating activities of continuing operations:** |  |  |
| Net loss | $(1976715) | $(3137381) |
| Loss from discontinued operations, net of income tax | - | (67350) |
| Net loss from continuing operations | (1976715) | (3070031) |
| **Adjustments to reconcile net loss from continuing operations to net cash flows used in operating activities of continuing operations:** |  |  |
| Depreciation expense | 7720 | 20289 |
| Loss on disposal of property and equipment |  | 116981 |
| Non-cash lease expense | 70229 | 31662 |
| Gain on termination of lease |  | (9059) |
| Deferred income taxes |  | 27515 |
| Stock-based compensation | 2031 | 32280 |
| Changes in fair value of investments in marketable securities | 295997 | 1781664 |
| Changes in fair value of investment in warrants | 7065 | 51621 |
| Changes in fair value of derivative liability | 870 |  |
| Gain on settlement of asset retirement obligations |  | (45873) |
| **Changes in assets and liabilities:** |  |  |
| Accounts receivable | 135238 | (180823) |
| Prepaid expenses | 66924 | 50591 |
| Other assets | 107886 | (26711) |
| Accounts payable and accrued expenses | 85404 | (97118) |
| Accounts payable and accrued expenses – related party | (28338) | (24224) |
| Accrued payroll and other employee costs | 154736 | (23483) |
| Due to related party | 125 | (884) |
| Operating lease liabilities | (60127) | (24435) |
| Income tax payables | (9785) | (80196) |
| Deferred revenue | (25747) | (233911) |
| Other liabilities | 12897 | 12686 |
| **Net cash flows used in operating activities of continuing operations** | **(1153590)** | **(1691459)** |
| **Cash flows from investing activities of continuing operations:** |  |  |
| Purchases of property and equipment | (954) |  |
| Proceeds from sale of marketable securities | - | 462763 |
| **Net cash flows provided by (used in) investing activities of continuing operations** | **(954)** | **462763** |
| **Cash flows from financing activities of continuing operations:** |  |  |
| Payments for finance lease |  | (4071) |
| Repayment of long-term debts | (12382) | (10561) |
| Repayment of related party debt | (6000) |  |
| Repayment of insurance premium financing | (23657) | (28559) |
| Net repayment of factoring arrangement | (11474) | (45341) |
| Proceeds from issuance of common shares related to at the market offering agreement |  | 30445 |
| Proceeds from collection of subscription receivable |  | 103942 |
| Proceeds from exercise of stock options | - | 117000 |
| **Net cash flows provided by (used in) financing activities of continuing operations** | **(53513)** | **162855** |
| **Cash flows from discontinued operations:** |  |  |
| Net cash flows used in operating activities of discontinued operations |  | (309332) |
| Net cash flows provided by investing activities of discontinued operations |  | 10298 |
| Net cash flows used in financing activities of discontinued operations | - | (19915) |
| **Net cash flows used in discontinued operations** | **-** | **(318949)** |
| Effect of exchange rate changes | (3872) | 2685 |
| Net change in cash and cash equivalents | (1211929) | (1382105) |
| Cash and cash equivalents – beginning of the period | 1985962 | 2121089 |
| **Cash and cash equivalents – end of the period** | $**774033** | $**738984** |
| **Supplemental cash flow disclosures:** |  |  |
| Interest paid | $16625 | $22857 |
| Income taxes paid (received), net | $(4574) | $93586 |
| **Non-cash investing and financing transactions:** |  |  |
| Insurance premium financing | $108000 | $139500 |
| Dividends accrued on Series A convertible preferred shares | $27968 | $- |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $552577 | $- |

---

The accompanying notes are an integral part of these unaudited consolidated financial statements.

**HEARTCORE ENTERPRISES, INC.**

**NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS**

HeartCore Enterprises, Inc. ("HeartCore USA"), a holding company, was incorporated under the laws of the State of Delaware on May 18, 2021.

On July 16, 2021, HeartCore USA executed a share exchange agreement with certain shareholders of HeartCore Co., Ltd. ("HeartCore Japan"), a company that was incorporated in Japan on June 12, 2009. Pursuant to the terms of the share exchange agreement, HeartCore USA issued 15,999,994 shares of its common shares to the shareholders of HeartCore Japan in exchange for 10,706 shares out of 10,984 shares of common shares issued by HeartCore Japan, representing approximately 97.5% of HeartCore Japan's outstanding common shares. On February 24, 2022, HeartCore USA purchased the remaining 278 shares of common shares of HeartCore Japan. As a result, HeartCore Japan became a wholly-owned operating subsidiary of HeartCore USA.

The share exchange on July 16, 2021 has been accounted for as a recapitalization between entities under common control since the same controlling shareholders controlled these two entities before and after the transaction. The consolidation of HeartCore USA and its subsidiary has been accounted for at historical cost and prepared on the basis as if the transaction had become effective as of the beginning of the earliest period presented in the unaudited consolidated financial statements.

HeartCore USA, via its wholly-owned operating subsidiary, HeartCore Japan, is mainly engaged in the business of developing and sales of comprehensive software. Beginning from early 2022, HeartCore USA is engaged in the business of providing consulting services to Japanese companies with intention to go public in the United States capital market.

On September 6, 2022, HeartCore USA entered into a share exchange and purchase agreement to acquire 51% of the outstanding shares of Sigmaways, Inc. ("Sigmaways"), a company incorporated under the laws of the State of California in April 2006, and its wholly-owned subsidiaries, Sigmaways B.V. and Sigmaways Technologies Ltd. ("Sigmaways Technologies"). Sigmaways B.V. was incorporated in Netherlands in November 2019. Sigmaways Technologies was incorporated in Canada in August 2020. Sigmaways and its wholly-owned subsidiaries are primarily engaged in the business of providing software development and other services in the United States. The acquisition was closed on February 1, 2023.

In January 2023, HeartCore USA incorporated a wholly-owned subsidiary, HeartCore Financial, Inc. ("HeartCore Financial"), under the laws of the State of Delaware. HeartCore Financial is engaged in the business of providing consulting services.

In November 2023, HeartCore Japan established a 51% owned subsidiary in Vietnam, HeartCore Luvina Vietnam Company Limited ("HeartCore Luvina"), which is engaged in the business of providing software development and other services. HeartCore Luvina started its operations from February 2024. In October 2025, HeartCore Japan transferred 51% of the outstanding shares of HeartCore Luvina to HeartCore USA.

In April 2024, HeartCore Financial incorporated a branch office, HeartCore Financial, Inc. – Japan Branch Office ("HeartCore Financial – Japan"), in Japan. HeartCore Financial – Japan is engaged in the business of providing consulting services.

On July 24, 2025, the Board of Directors approved to enter into a non-binding letter of intent to sell 100% of the outstanding shares of HeartCore Japan. The sale of HeartCore Japan represented a strategic shift that had a major impact on the results of operations and has been accounted for as a discontinued operation (see NOTE 16). The sale transaction was closed on October 31, 2025.

In October 2025, HeartCore USA incorporated a wholly-owned subsidiary, Higgs Field Co., Ltd. ("Higgs Field"), in Japan. Higgs Field is engaged in the business of providing business and management consulting services.

HeartCore USA, HeartCore Japan, Sigmaways, Sigmaways B.V., Sigmaways Technologies, HeartCore Financial, HeartCore Luvina, HeartCore Financial – Japan and Higgs Field are hereafter referred to as the "Company" unless specific reference is made to an entity.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation and Principles of Consolidation**

The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim consolidated financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The unaudited consolidated financial statements include the accounts of the Company and its subsidiaries. The Company has presented the results of operations and cash flows of HeartCore Japan as discontinued operations in the unaudited consolidated financial statements as of and for all periods presented. All footnotes exclude activities of HeartCore Japan unless otherwise noted. All significant intercompany accounts and transactions have been eliminated.

These unaudited interim consolidated financial statements do not include all of the information and disclosures required by the U.S. GAAP for complete consolidated financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments consisting of normal recurring nature considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been included. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2025.

**Liquidity and Going Concern**

The unaudited consolidated financial statements have been prepared in accordance with U.S. GAAP assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company assesses whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.

For the three months ended March 31, 2026, the Company incurred net loss from continuing operations of $2.0 million and net cash flows used in operating activities of continuing operations of $1.2 million, primarily due to the macroeconomic downturn environment. As of March 31, 2026, the Company had cash and cash equivalents of $0.8 million, working capital of $1.0 million and accumulated deficit of $15.6 million. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company's plan is to continue exploring strategic alternatives for raising additional funding for future operations through a combination of obtaining equity financing, entering into debt or other financing arrangements, and restructuring of operations to grow revenues and decrease expenses to supplement the Company's liquidity. The Company's ability to raise capital may be constrained by the price of and demand for the Company's equity shares. Additional funding may not be available on favorable terms or at all, and could further dilute the Company's current shareholders. Management cannot conclude as of the date of this report that its plans are probable of being successfully implemented. There can be no assurance that the Company will be able to obtain sufficient additional liquidity when needed or under acceptable terms, if at all.

The unaudited consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company is unable to continue as a going concern.

**Use of Estimates**

In preparing the unaudited consolidated financial statements in conformity U.S. GAAP, the management is required to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information available as of the date of the unaudited consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, allowance for credit losses, useful life of property and equipment, impairment of long-lived assets, valuation of stock-based compensation, valuation allowance of deferred tax assets, uncertain tax positions, implicit interest rate of operating and finance leases, valuation of investment in warrants, and valuation of derivative liability. Actual results could differ from those estimates.

**Investment in Warrants**

Investment in warrants represents stock warrants earned from its consulting service customers. The warrants are measured at fair value and any changes in fair value are recognized in other income (expenses). Investment in warrants is classified as long-term if the warrants are exercisable over one year after the date of receipt.

**Investments in Marketable Securities**

Investments in marketable securities represent equity securities registered for public sale with readily determinable fair value. The marketable securities are obtained through stocks of its customers received as noncash consideration from consulting services and through exercise of stock warrants of its consulting service customers and measured at fair value with any changes in fair value recognized in other income (expenses).

**Impairment of Long-Lived Assets**

Long-lived assets with finite lives, primarily property and equipment and operating lease right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated cash flows from the use of the asset and its eventual disposition are below the asset's carrying value, then the asset is deemed to be impaired and written down to its fair value. There were no impairments of these assets during the three months ended March 31, 2026 and 2025.

**Foreign Currency Translation**

The functional currency of HeartCore Japan, HeartCore Financial – Japan and Higgs Field is the Japanese Yen ("JPY"). The functional currency of HeartCore USA, HeartCore Financial and Sigmaways is the United States Dollar ("US$"). The functional currency of Sigmaways B.V. is the Euro ("EUR"). The functional currency of Sigmaways Technologies is the Canada Dollar ("CAD"). The functional currency of HeartCore Luvina is the Vietnam Dong ("VND"). Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the unaudited consolidated statements of operations and comprehensive loss.

The reporting currency of the Company is the US$, and the unaudited consolidated financial statements have been expressed in US$. In accordance with the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 830-30, "Translation of Financial Statements", assets and liabilities of the Company whose functional currency is not US$ are translated into US$, using the exchange rates on the balance sheet dates. Revenues and expenses are translated at average rates prevailing during the periods. The gains and losses resulting from the translation of financial statements are recorded as a separate component of accumulated other comprehensive income (loss) within the unaudited consolidated statements of changes in shareholders' equity.

**Revenue Recognition**

The Company recognizes revenues under ASC Topic 606, "Revenue from Contracts with Customers".

To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenues when (or as) the Company satisfies a performance obligation. Revenues amount represents the invoiced value, net of a value-added tax ("Consumption Tax") and applicable local government levies. The Consumption Tax on sales are calculated at 10% of gross sales in Japan and Vietnam, 5% of gross sales in Canada, 21% of gross sales in Netherlands and nil of gross sales in the United States.

The Company currently generates its revenues from the following main sources:

*<u>Revenues from Software Development Services</u>*

The Company provides customers with software development and support services pursuant to their specific requirements, which primarily compose of consulting, integration, training, custom application and workflow development. The Company recognizes revenues at a point in time when control is transferred to the customers and the Company is entitled to the payment, which is when the promised services are delivered and accepted by the customers.

*<u>Revenues from Customized Software Development and Services</u>*

The Company's customized software development and services revenues primarily include revenues from providing software development solutions and other support services to its customers. The contract pricing is at stated billing rates per hour. These contracts are generally short-term in nature and not longer than one year in duration. For services provided under the contracts that result in the transfer of control over time, the underlying deliverable in the contracts is owned and controlled by the customers and does not create an asset with an alternative use to the Company. The Company recognizes revenues on rate per hour contracts based on the amount billable to the customers, as the Company has the right to invoice the customers in an amount that directly corresponds with the value to the customers of the Company's performance to date.

*<u>Revenues from Consulting Services</u>*

The Company provides public listing related consulting services to customers pursuant to the specific requirements prescribed in the contracts, which primarily include communicating with intermediary parties, preparing required documents related to the initial public offering and supporting the listing process. The consulting services contracts normally include both cash and noncash considerations. Cash consideration is paid in installment payments and is recognized in revenues over the period of the contract by reference to progress toward complete satisfaction of that performance obligation. Noncash consideration is in the form of stocks and warrants of the customers and is measured at fair value at contract inception. Noncash consideration that is variable for reasons other than only the form of the consideration is included in the transaction price, but is subject to the constraint on variable consideration. The Company assesses the estimated amount of the variable noncash consideration at contract inception and subsequently, to determine when and to what extent it is probable that a significant reversal of cumulative revenues recognized will not occur once the uncertainty associated with the variable consideration is subsequently resolved. Only when the significant revenues reversal is concluded probable of not occurring can variable consideration be included in revenues. Based on evaluation of likelihood and magnitude of a reversal in applying the constraint, the variable noncash consideration is recognized in revenues until the underlying uncertainties have been resolved.

*<u>Sales Returns and Allowances</u>*

The Company records reduction to revenues for estimated customer returns and allowances. The Company bases its estimates on historical rates of customer returns and allowances as well as the specific identification of outstanding returns. The actual amount of customer returns and allowances, which is inherently uncertain, may differ from the Company's estimates. If the Company determines that actual or expected returns or allowances are significantly higher or lower than the reserves it established, it would record a reduction or increase, as appropriate, to revenues in the period in which it makes such a determination. Reserves for customer refunds are included within other current liabilities on the consolidated balance sheets. At a minimum, the Company reviews and refines these estimates on a quarterly basis.

*<u>Contract Balances</u>*

The timing of revenue recognition may differ from the timing of invoicing to the customers. The Company determines that its contracts do not include a significant financing component. The Company records a contract asset, which is included in accounts receivable in the consolidated balance sheets, when revenues are recognized prior to invoicing. The Company factors certain accounts receivable upon or after the performance obligation is being met. The Company records deferred revenue in the consolidated balance sheets when revenues are recognized subsequent to cash collection for an invoice. Deferred revenue is reported net of related uncollected deferred revenue in the consolidated balance sheets. The amounts of revenues recognized during the three months ended March 31, 2026 and 2025 that were included in the opening deferred revenue balances were approximately $0.1 million and $0.2 million, respectively.

*<u>Disaggregation of Revenues</u>*

The Company disaggregates its revenues from contracts by revenue stream types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenues and cash flows are affected by economic factors. The Company's disaggregation of revenues by revenue stream for the three months ended March 31, 2026 and 2025 is as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months** | **For the Three Months** |
|  | **Ended March 31,** | **Ended March 31,** |
|  | **2026** | **2025** |
| Revenues from software development services | $206751 | $7089 |
| Revenues from customized software development and services | 1013346 | 1840781 |
| Revenues from consulting services | 25747 | 245543 |
| Total revenues | $1245844 | $2093413 |

---

**Concentration of Credit Risk**

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts receivable, note receivable and other receivable. The Company usually does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.

For the three months ended March 31, 2026 and 2025, customers account for 10% or more of the Company's revenues are as follows:

SCHEDULE OF CONCENTRATION OF CREDIT RISK

---

| | | |
|:---|:---|:---|
|  | **For the Three Months** | **For the Three Months** |
|  | **Ended March 31,** | **Ended March 31,** |
|  | **2026** | **2025** |
| Customer A | 32.0% | 32.1% |
| Customer B | 16.6% | \* |
| Customer C | 13.7% | 12.4% |
| Customer D | 11.3% | 10.3% |
| Customer E | \* | 10.4% |

---

As of March 31, 2026 and December 31, 2025, customers account for 10% or more of the Company's accounts receivable are as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Customer A | 18.8% | 21.3% |
| Customer D | 16.5% | 12.9% |

---

For the three months ended March 31, 2026 and 2025, vendor accounts for 10% or more of the Company's purchases is as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months** | **For the Three Months** |
|  | **Ended March 31,** | **Ended March 31,** |
|  | **2026** | **2025** |
| Vendor A | 14.2% | 18.5% |

---

As of March 31, 2026 and December 31, 2025, vendor accounts for 10% or more of the Company's accounts payable and accrued expenses is as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Vendor B | 13.1% | 14.0% |

---

\* Less than 10%.

**Segment Reporting**

ASC Topic 280, "Segment Reporting", requires use of the management approach model for segment reporting. The management approach model is based on the way a company's chief operating decision maker ("CODM") organizes segments within the Company for making operating decisions, assessing performance and allocating resources. Reportable segments are based on services, geography, legal structure, management structure, or any other manner in which management disaggregates a company (see NOTE 17).

**Series A Convertible Preferred Shares and Derivative Liability**

When the Company issues the Series A convertible preferred shares (see NOTE 14), it first evaluates the balance sheet classification of the convertible instrument in its entirety to determine whether the instrument should be classified as a liability under ASC Topic 480, "Distinguishing Liabilities from Equity", and second evaluates whether the conversion feature should be accounted for separately from the host instrument. A conversion feature of the Series A convertible preferred shares would be separated from the convertible instrument and classified as a derivative liability if the conversion feature, as a standalone instrument, meets the definition of an embedded derivative under ASC Topic 815, "Derivatives and Hedging". Generally, characteristics that require derivative treatment include, among others, when the conversion feature is not indexed to the Company's equity, as defined in ASC Topic 815-40, or when it must be settled either in cash or by issuing equity shares that are readily convertible to cash.

The Company assesses the Series A convertible preferred shares as a whole and determines it does not meet the liability classification pursuant to ASC Topic 480 and the Company classifies the host instrument as permanent equity because no features provide for redemption by the holders of the Series A convertible preferred shares or conditional redemption, which is not solely within the Company's control, and there are no unconditional obligations in that (i) the Company must or may settle in a variable number of its equity shares, and (ii) the monetary value is predominantly fixed, varying with something other than the fair value of the Company's equity shares or varying inversely in relation to the Company's equity shares.

The Company assesses the conversion feature of the Series A convertible preferred shares for derivative accounting consideration and determines it meets the definition of an embedded derivative, which is separated from the host instrument and classified as a derivative liability carried on the consolidated balance sheets at fair value with any changes in fair value recognized in other income (expenses). The Company values the fair value of derivative liability using the income approach with the discounted cash flow valuation method with the assistance of a third-party valuation appraiser. The determination of fair value requires management to make significant estimates and assumptions related to forecasted cash flows and discount rate.

**Fair Value Measurements**

The Company performs fair value measurements in accordance with ASC Topic 820, "Fair Value Measurements and Disclosures". Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset's or a liability's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC Topic 820 establishes three levels of inputs that may be used to measure fair value:

● Level 1: quoted prices in active markets for identical assets or liabilities;

● Level 2: inputs other than Level 1 that are observable, either directly or indirectly; or

● Level 3: unobservable inputs that are supported by little or no market activities and that are significant to the fair values of the assets or liabilities.

As of March 31, 2026 and December 31, 2025, the carrying values of current assets, except for investments in marketable securities, and current liabilities, except for derivative liability, approximated their fair values reported in the consolidated balance sheets due to the short-term maturities of these instruments.

Assets and liabilities measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 are summarized below (also see NOTE 5 for investments):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fair Value Measurements as of March 31, 2026** | **Fair Value Measurements as of March 31, 2026** | **Fair Value Measurements as of March 31, 2026** | **Fair Value Measurements as of March 31, 2026** | **Fair Value Measurements as of March 31, 2026** |
|  | **Quoted Prices<br> in Active <br> Markets for Identical<br> Assets<br> (Level 1)** | **Significant Other<br> Observable<br> Inputs<br> (Level 2)** | **Unobservable<br> Inputs<br> (Level 3)** | **Fair Value at<br> March 31, 2026** |
| Investments in marketable securities | 3394190 |  |  | 3394190 |
| Long-term investment in warrants |  | 273859 |  | 273859 |
| Derivative liability |  |  | 122589 | 122589 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fair Value Measurements as of December 31, 2025** | **Fair Value Measurements as of December 31, 2025** | **Fair Value Measurements as of December 31, 2025** | **Fair Value Measurements as of December 31, 2025** | **Fair Value Measurements as of December 31, 2025** |
|  | **Quoted Prices<br> in Active <br> Markets for Identical<br> Assets<br> (Level 1)** | **Significant Other<br> Observable<br> Inputs<br> (Level 2)** | **Unobservable<br> Inputs<br> (Level 3)** | **Fair Value at<br> December 31, 2025** |
| Investments in marketable securities | 3690187 |  |  | 3690187 |
| Long-term investment in warrants |  | 280924 |  | 280924 |
| Derivative liability |  |  | 121719 | 121719 |

---

**Discontinued Operations**

In accordance with ASC Topic 205-20, "Presentation of Financial Statements – Discontinued Operations", a component or a group of components of an entity shall be classified as held for sale in the period in which all of the following criteria are met: (i) management, having the authority to approve the action, commits to a plan to sell the entity to be sold; (ii) the entity to be sold is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such entities to be sold; (iii) an active program to locate a buyer or buyers and other actions required to complete the plan to sell the entity to be sold have been initiated; (iv) the sale of the entity to be sold is probable and transfer of the entity to be sold is expected to qualify for recognition as a completed sale within one year; (v) the entity to be sold is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and (vi) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. A component or a group of components of an entity classified as held for sale is reported at the lower of its carrying amount or fair value less cost to sell. If the fair value of the entity to be sold less cost to sell is lower than its carrying amount, an impairment loss is recognized and update each reporting period as appropriate.

The results of operations of the entity to be sold classified as held for sale are reported as discontinued operations if the disposal represents a strategic shift that has or will have a major effect on an entity's operations and financial results.

The Company assesses the sale of HeartCore Japan and determines it meets the held for sale criteria and the discontinued operations criteria. The results of operations of HeartCore Japan are presented as discontinued operations in the unaudited consolidated statements of operations and comprehensive loss for all periods presented. Prior periods have been adjusted to conform to the current presentation. The required disclosures are included in NOTE 16.

**Recent Accounting Pronouncements**

In November 2024, the FASB issued Accounting Standards Update ("ASU") No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public companies to disclose additional information about specific expense categories in the notes to the consolidated financial statements on an annual and interim basis. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU No. 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its unaudited interim consolidated financial statements and related disclosures.

**NOTE 3 – ACCOUNTS RECEIVABLE**

Accounts receivable consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Accounts receivable – non-factored | $434460 | $534710 |
| Accounts receivable – factored with recourse | 138087 | 173155 |
| Total accounts receivable, gross | 572547 | 707865 |
| Less: allowance for credit losses | - | - |
| Total accounts receivable | $572547 | $707865 |

---

**NOTE 4 – RELATED PARTY TRANSACTIONS**

As of March 31, 2026 and December 31, 2025, the Company had due to related party balances of $401 and $285, respectively, from Sumitaka Yamamoto, the Chief Executive Officer ("CEO") and major shareholder of the Company. The balance is unsecured, non-interest bearing and due on demand. During the three months ended March 31, 2026 and 2025, the related party paid operating expenses on behalf of the Company and received the payments in a net amount of $125 and nil, respectively.

As of March 31, 2026 and December 31, 2025, the Company had accounts payable and accrued expenses balances of $96,333 and $124,618, respectively, to Luvina Software Joint Stock Company ("Luvina Software"), the non-controlling shareholder of HeartCore Luvina. During the three months ended March 31, 2026 and 2025, the Company engaged the related party for software development and other support services of $114,535 and $42,810, respectively. During the three months ended March 31, 2026 and 2025, the Company repaid to the related party for operating expenses the related party paid on behalf of the Company of nil and $884, respectively.

As of March 31, 2026 and December 31, 2025, the Company had short-term debt balances of $69,000 and $75,000, respectively, to Prakash Sadasivam, the CEO and non-controlling shareholder of Sigmaways and its subsidiaries. The debt is borrowed from the related party for working capital purpose. The balance is unsecured, bears an annual interest of 7.5% and due on demand. During the three months ended March 31, 2026 and 2025, the Company repaid to the related party of $6,000 and nil, respectively.

**NOTE 5 – INVESTMENTS**

*<u>Investment in Warrants</u>*

The Company received warrants from its customers as noncash consideration from consulting services. The warrants are not registered for public sale and are initially measured at fair value at contract inception. The Company's investment in warrants is measured on a recurring basis and carried on the consolidated balance sheets at an estimated fair value at the end of the period. The valuation of investment in warrants is determined using the Black-Scholes model based on the stock price, exercise price, expected volatility, time to maturity and risk-free interest rate for the term of the warrants.

The following table summarizes the Company's investment in warrants activities for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| Fair value of investment in warrants at beginning of the period | $280924 | $577786 |
| Changes in fair value of investment in warrants | (7065) | (51621) |
| Fair value of investment in warrants at end of the period | $273859 | $526165 |

---

*<u>Investments in Marketable Securities</u>*

The Company's investments in marketable securities represent stocks received from its customers as noncash consideration from consulting services and stocks received upon the exercise of warrants described above. They are registered for public sale with readily determinable fair values, and are measured at quoted prices on a recurring basis at the end of the period.

The following table summarizes the Company's investments in marketable securities activities for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| Fair value of investments in marketable securities at beginning of the period | $3690187 | $4495703 |
| Changes in fair value of investments in marketable securities | (295997) | (1781664) |
| Marketable securities sold | - | (462763) |
| Fair value of investments in marketable securities at end of the period | $3394190 | $2251276 |

---

**NOTE 6 – PROPERTY AND EQUIPMENT, NET**

Property and equipment, net consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Machinery and equipment | $338426 | $343150 |
| Vehicle | 79704 | 81420 |
| Subtotal | 418130 | 424570 |
| Less: accumulated depreciation | (138945) | (132981) |
| Total property and equipment, net | $279185 | $291589 |

---

For the three months ended March 31, 2026 and 2025, the Company recognized depreciation expenses of $7,720 and $20,289, respectively.

**NOTE 7 – LEASES**

The Company has entered into operating leases for office space with terms ranging from two to three years, and finance lease for vehicle with terms of five years. The estimated effect of lease renewal and termination options, as applicable, that are reasonably certain to be exercised in the determination of the lease term and initial measurement of lease right-of-use assets and lease liabilities is included in the unaudited consolidated financial statements.

Operating leases costs for lease payments are recognized on a straight-line basis over the lease term. Finance lease costs include amortization, which is recognized on a straight-line basis over the expected life of the leased assets, and interest expense, which is recognized following an effective interest rate method. Leases with initial term of twelve months or less are not recorded in the consolidated balance sheets.

The components of lease costs for the three months ended March 31, 2026 and 2025 are as follows:

SCHEDULE OF COMPONENTS OF LEASE COST

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| Finance lease costs |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of finance lease right-of-use assets | $- | $4179 |
| &nbsp;&nbsp;&nbsp;Interest on finance lease liabilities | - | 198 |
| Total finance lease costs |  | 4377 |
| Operating leases costs | 73522 | 33145 |
| Total leases costs | $73522 | $37522 |

---

The following table presents supplemental information related to the Company's leases for the three months ended March 31, 2026 and 2025:

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO COMPANY LEASE

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Operating cash flows from finance lease | $- | $198 |
| &nbsp;&nbsp;&nbsp;Operating cash flows from operating leases | 61350 | 25185 |
| &nbsp;&nbsp;&nbsp;Financing cash flows from finance lease |  | 4071 |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 552577 |  |
| Remeasurement of operating lease liabilities and right-of-use assets due to lease modification | 21970 |  |
| Weighted average remaining lease term (years): |  |  |
| &nbsp;&nbsp;&nbsp;Finance lease |  | 3.5 |
| &nbsp;&nbsp;&nbsp;Operating leases | 1.7 | 0.8 |
| Weighted average discount rate (per annum): |  |  |
| &nbsp;&nbsp;&nbsp;Finance lease | 0.00% | 1.32% |
| &nbsp;&nbsp;&nbsp;Operating leases | 1.45% | 4.23% |

---

As of March 31, 2026, the future maturity of lease liabilities is as follows:

SCHEDULE OF FUTURE MINIMUM MATURITIES OF OPERATING LEASE LIABILITIES

---

| | |
|:---|:---|
| <br>**Year Ended December 31,** | **Operating**<br>**Leases** |
| Remaining of 2026 | $238721 |
| 2027 | 283420 |
| 2028 |  |
| 2029 |  |
| 2030 |  |
| Thereafter | - |
| Total lease payments | 522141 |
| Less: imputed interest | (2478) |
| Total lease liabilities | 519663 |
| Less: current portion | (308119) |
| Non-current lease liabilities | $211544 |

---

Pursuant to the operating lease agreements, the Company made security deposits to the lessors. The security deposits amounted to $278,154 and $282,958 as of March 31, 2026 and December 31, 2025, respectively.

**NOTE 8 – OTHER CURRENT LIABILITIES**

Other current liabilities consist of the following:

SCHEDULE OF OTHER CURRENT LIABILITIES

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Customer refund liability\* | $500000 | $500000 |
| Others | 98602 | 86175 |
| Total other current liabilities | $598602 | $586175 |

---

\* On June 28, 2024, the Company entered into a settlement agreement with a customer, pursuant to which the consulting services agreement with the customer was terminated and the Company would refund $500,000 to the customer in August 2025. As of the date of this report, the Company did not make payment to the customer.

**NOTE 9 – FACTORING LIABILITY**

Sigmaways, the subsidiary acquired by the Company in February 2023, entered into a factoring and security agreement ("Factoring Agreement") with The Southern Bank Company, an unrelated factor ("Factor"), in February 2017, for the purpose of factoring certain accounts receivable. Pursuant to the terms of the Factoring Agreement, Sigmaways may offer for sale, and the Factor may purchase in its sole discretion, certain accounts receivable of Sigmaways ("Purchased Receivable"). The Factoring Agreement provided for a maximum of $850,000 in Purchased Receivable.

Selected accounts receivable is submitted to the Factor, and Sigmaways receives 90% of the face value of the accounts receivable by wire transfer. Upon payment by the customers, the remainder of the amount due is received from the Factor after deducting certain fees.

The Factoring Agreement specifies that eligible accounts receivable is factored with recourse. Pursuant to the terms of the recourse provision, Sigmaways is required to reimburse the Factor, upon demand, for Purchased Receivable that is not paid on time by the customers. The performance of all obligations and payments to the Factor is secured by all Sigmaways' now owned and hereafter assets and any sums maintained by the Factor that are identified as payable to Sigmaways.

The Factoring Agreement has an initial term of twelve months and automatically renews for successive twelve-month renewal periods unless terminates pursuant to the terms of the Factoring Agreement. Sigmaways may terminate the Factoring Agreement with sixty days' written notice to the Factor and is subject to certain early termination fee.

The Factoring Agreement contains covenants that are customary for accounts receivable-based factoring agreements and also contains provisions relating to events of default that are customary for agreements of this type.

As of March 31, 2026 and December 31, 2025, there were $124,508 and $135,982 borrowed and outstanding under the Factoring Agreement, respectively. There are various fees charged by the Factor, including initial discount purchase fee, factoring fee and interest expense. For the three months ended March 31, 2026 and 2025, the Company recorded $10,142 and $8,901 in interest expenses related to Factoring Agreement, respectively.

**NOTE 10 – INSURANCE PREMIUM FINANCING**

In January 2026, the Company entered into an insurance premium financing agreement with AFCO Direct, a division of AFCO Credit Corporation, for $108,000 at an annual interest rate of 13.9% for ten months from February 1, 2026, payable in ten monthly installments of principal and interest.

In January 2025, the Company entered into an insurance premium financing agreement with AFCO Direct, a division of AFCO Credit Corporation, for $139,500 at an annual interest rate of 13.9% for eleven months from February 1, 2025, payable in eleven monthly installments of principal and interest.

As of March 31, 2026 and December 31, 2025, the balances of the insurance premium financing were $97,773 and $13,430, respectively. For the three months ended March 31, 2026 and 2025, the Company recorded $1,423 and $1,832 in interest expenses related to insurance premium financing, respectively.

**NOTE 11 – LONG-TERM DEBTS**

The Company's long-term debts represent loans borrowed from a bank and a financial institution as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name of Bank/Financial Institution** | **Amount<br> Borrowed** | **Loan<br> Duration** | **Annual<br> Interest<br> Rate** | **Balance as of<br> March 31, 2026** | **Balance as of<br> December 31, 2025** |
| First Home Bank | $350000 (a) | 4/18/2019 – 4/18/2029 | Wall Street Journal U.S. Prime Rate + 2.75% | $147701 | $157923 |
| U.S. Small Business Administration | 350000 (a) | 5/30/2020 – 5/30/2050 | 3.75% | 338891 | 341051 |
| Aggregate outstanding principal balances |  |  |  | 486592 | 498974 |
| Less: current portion |  |  |  | (51697) | (50598) |
| Non-current portion |  |  |  | $434895 | $448376 |

---

(a) These debts are guaranteed
 by Prakash Sadasivam, the CEO and non-controlling shareholder of Sigmaways and its subsidiaries, and secured by all assets of Sigmaways.

For the three months ended March 31, 2026 and 2025, the Company recorded $5,060 and $7,061 in interest expenses related to long-term debts, respectively.

As of March 31, 2026, future minimum principal payments for long-term debts are as follows:

SCHEDULE OF FUTURE MINIMUM LOAN PAYMENTS

---

| | |
|:---|:---|
| <br>**Year Ended December 31,** | **Principal**<br>**Payment** |
| Remaining of 2026 | $38216 |
| 2027 | 55325 |
| 2028 | 60471 |
| 2029 | 27857 |
| 2030 | 9973 |
| Thereafter | 294750 |
| Total | $486592 |

---

**NOTE 12 – INCOME TAXES**

*<u>United States</u>*

HeartCore USA, Sigmaways and HeartCore Financial, incorporated in the United States, are subject to federal income tax at 21% statutory tax rate with respect to the profit generated from the United States.

*<u>Netherlands</u>*

Sigmaways B.V. is a company incorporated in Netherlands. The first EUR200,000 of taxable income is subject to a statutory tax rate of 19% and the remaining taxable income is subject to a statutory tax rate of 25.80%.

*<u>Canada</u>*

Sigmaways Technologies is a company incorporated in British Columbia in Canada. It is subject to income tax on income arising in, or derived from, the tax jurisdiction in British Columbia it operates. The basic federal rate of Part I tax is 38% of taxable income, 28% after federal tax abatement. After the general tax reduction, the net federal tax rate is 15%. The provincial and territorial lower and higher tax rates in British Columbia are 2% and 12%, respectively.

*<u>Vietnam</u>*

HeartCore Luvina is a company incorporated in Vietnam. It is subject to standard income tax rate at 20% with respect to the taxable income.

*<u>Japan</u>*

HeartCore Financial – Japan and Higgs Field are companies incorporated in Japan. Income taxes in Japan are imposed by the national, prefectural and municipal governments, and in the aggregate result in an effective statutory tax rate of approximately 34.59%.

For the three months ended March 31, 2026 and 2025, the Company's income tax expense are as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| Current | $17469 | $12093 |
| Deferred | - | 27515 |
| Income tax expense | $17469 | $39608 |

---

For the three months ended March 31, 2026 and 2025, the effective tax rate were 0.89% and 1.31%, respectively.

**NOTE 13 – STOCK-BASED COMPENSATION**

On August 6, 2021, the Board of Directors and shareholders of the Company approved a 2021 Equity Incentive Plan ("2021 Plan"), under which 120,000 shares of common shares are authorized for issuance.

On August 1, 2023, the Board of Directors of the Company approved a 2023 Equity Incentive Plan ("2023 Plan"), under which 100,000 shares of common shares are authorized for issuance.

*<u>Stock Options</u>*

On December 25, 2021, the Company awarded stock options to purchase 76,725 shares of common shares pursuant to the 2021 Plan at an exercise price of $50.00 per share to various officers, directors, employees and consultants of the Company. The stock options vest on each annual anniversary of the date of issuance, in an amount equal to 25% of the applicable shares of common shares, with the expiration date on December 25, 2031.

On August 9, 2022, the Company awarded stock options to purchase 725 shares of common shares at an exercise price of $49.60 per share to three prior employees of the Company. The stock options are fully vested and exercisable on the grant date, with the expiration date on August 9, 2026.

On February 3, 2023, the Company awarded stock options to purchase 5,000 shares of common shares pursuant to the 2021 Plan at an exercise price of $23.40 per share to an employee of the Company. The stock options vest 50% on the grant date and February 1, 2024, respectively, with the expiration date on February 3, 2033.

The following table summarizes the stock options activities and related information for the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of**<br> **Stock Options** | **Weighted**<br> **Average**<br> **Exercise**<br> **Price** | **Weighted**<br> **Average**<br> **Remaining**<br> **Term**<br> **(Years)** | **Intrinsic**<br> **Value** |
| As of January 1, 2025 | 75325 | $48.23 | 7.01 | $64500 |
| Granted |  |  |  |  |
| Exercised | (5000) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.40 |  |  |
| Forfeited | - |  |  |  |
| As of March 31, 2025 | 70325 | $50.00 | 6.68 | $- |
| As of January 1, 2026 | 56075 | $49.99 | 5.92 | $- |
| Granted |  |  |  |  |
| Exercised |  |  |  |  |
| Forfeited | - |  |  |  |
| As of March 31, 2026 | 56075 | $49.99 | 5.67 | $- |
| Vested and exercisable as of March 31, 2026 | 56075 | $49.99 | 5.67 | $- |

---

For the three months ended March 31, 2026 and 2025, the Company recognized stock-based compensation related to stock options of nil and $30,676, respectively. There was no outstanding unamortized stock-based compensation related to stock options as of March 31, 2026.

*<u>Restricted Stock Units ("RSUs")</u>*

On February 9, 2022, the Company entered into executive employment agreements with five executives and granted 4,291 RSUs pursuant to the 2021 Plan. The RSUs vest on each annual anniversary of the date of the employment agreements, in an amount equal to 25% of the applicable shares of common shares. The fair value of the RSUs at grant date is $424,809.

The following table summarizes the RSUs activities and related information for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Number of RSUs** | **Weighted Average<br> Grant Date Fair**<br> **Value Per Share** |
| Unvested as of January 1, 2025 | 2146 | $99.00 |
| Granted |  |  |
| Vested | (1073) | 99.00 |
| Forfeited | (113) | 99.00 |
| Unvested as of March 31, 2025 | 960 | $99.00 |
| Unvested as of January 1, 2026 | 796 | $99.00 |
| Granted |  |  |
| Vested | (796) | 99.00 |
| Forfeited | - |  |
| Unvested as of March 31, 2026 | - | $- |

---

For the three months ended March 31, 2026 and 2025, the Company recognized stock-based compensation related to RSUs of $2,031 and $1,604, respectively. There was no outstanding unamortized stock-based compensation related to RSUs as of March 31, 2026.

**NOTE 14 – SHAREHOLDERS' EQUITY**

*<u>Shares Authorized</u>*

The Company is authorized to issue 200,000,000 shares of common shares, par value of $0.0001 per share, and 20,000,000 shares of preferred shares, par value of $0.0001 per share.

*<u>At the Market Offering Agreement ("ATM Agreement")</u>*

On October 23, 2023, the Company entered into a ATM Agreement with H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company's common shares, par value of $0.0001 per share, having an aggregate offering price of up to approximately $2 million ("ATM Shares"). The Company pays commission fees of 4% for each completed sale of ATM Shares pursuant to the terms of the ATM Agreement. For the three months ended March 31, 2026 and 2025, the Company sold a total of nil and 794 shares of the ATM Shares for net proceeds of nil and $30,445 after deducting commission fees and other transaction costs, respectively. The subscription receivable of $103,942 related to ATM Shares sold on December 31, 2024 was collected in full on January 2, 2025.

*<u>Designation of Series A Convertible Preferred Shares and Securities Purchase Agreement</u>*

On June 30, 2025, the Company filed a certificate of designations of preferences and rights of Series A convertible preferred shares ("Series A COD") with the Secretary of State of the State of Delaware to set forth the terms of the Series A convertible preferred shares. Pursuant to the Series A COD, the Company designated 2,000 shares of preferred shares as Series A convertible preferred shares and each share of Series A convertible preferred shares has a stated value of $1,100. On October 22, 2025, the Board of Directors of the Company approved to amend the number of designated shares of Series A convertible preferred shares to 4,000 shares pursuant to the Series A COD. The following summarizes the material terms of the Series A convertible preferred shares:

● Dividends – Each Series A convertible preferred shares holder ("Holder") shall be entitled to receive dividends of 10 % per annum on the stated value of each share of Series A convertible preferred shares.

● Liquidation – In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the Holders shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of common shares and any other class or series of equity shares of the Company, an amount per share equal to the greater of (i) the stated value plus all accrued and unpaid dividends thereon or (ii) the amount that such Holder would receive if such Holder converts all of its shares of Series A convertible preferred shares into common shares immediately prior to such liquidation, dissolution or winding up. If, upon any such liquidation, dissolution or winding up, the assets and funds available for distribution among the Holders shall be insufficient to permit the payment to such Holders of the full preferential amount aforesaid, then the entire assets and funds of the Company legally available for distribution shall be distributed ratably among the Holders in proportion to the amount that each such Holder is entitled to receive. After the payment of the full amount of the liquidation preference to which the Holders are entitled, the Holders shall have no right or claim to any of the remaining assets of the Company.

● Voting – The Series A convertible preferred shares shall have no voting rights. However, as long as any shares of Series A convertible preferred shares are outstanding, the Company shall not, without the affirmative vote of the Holders of a majority of the outstanding shares of Series A convertible preferred shares, and with each share of Series A convertible preferred shares having one vote on (i) alter or change adversely the powers, preferences or rights given to the Series A convertible preferred shares or alter or amend the Series A COD, (ii) issue additional shares of Series A convertible preferred shares or increase or decrease (other than by conversion) the number of authorized shares of Series A convertible preferred shares, or (iii) enter into any agreement with respect to any of the foregoing.

● Conversion – Each Holder shall have the right, at such Holder's opinion, to convert any or all of the Series A convertible preferred shares held by such Holder into fully paid and nonassessable shares of common shares. The number of shares of common shares issuable upon conversion of each share of Series A convertible preferred shares shall be equal to the quotient obtained by dividing (i) the stated value plus all accrued and unpaid dividends thereon by (ii) 90 % of the average of the two lowest volume weighted average price ("VWAP") of the Company's common shares for the five trading days immediately preceding the respective common shares conversion notice delivery date.

● Redemption – No share of Series A convertible preferred shares shall be redeemable under any circumstances.

On June 30, 2025, the Company entered into a securities purchase agreement and a registration rights agreement with Crom Structured Opportunities Fund I, LP ("Crom Structured"), pursuant to which the Company closed, issued and sold to Crom Structured an aggregate of 2,000 shares of the Company's designated Series A convertible preferred shares for net proceeds of $1,800,000 after deducting share issuance transaction fees.

For the three months ended March 31, 2026, no shares of Series A convertible preferred shares were converted into common shares.

For the three months ended March 31, 2026, dividends accrued on Series A convertible preferred shares amounted to $27,968.

*<u>Equity Purchase Agreement</u>*

On June 30, 2025, the Company entered into an equity purchase agreement and a registration rights agreement with Crom Structured, pursuant to which Crom Structured has committed to purchase up to $25 million in shares of the Company's common shares, subject to certain limitations and conditions set forth in the equity purchase agreement. The Company shall not issue or sell any shares of common shares under the equity purchase agreement which, when aggregate with all purchases of common shares made by Crom Structured pursuant to the equity purchase agreement, would result in beneficial ownership of more than 4.99% of the Company's outstanding shares of common shares.

Pursuant to the terms of the equity purchase agreement, the Company has the right, but not the obligation, to sell to Crom Structured, shares of common shares over the period commencing on the date of the equity purchase agreement and ending on the earlier of (i) the date on which Crom Structured shall have purchased common shares pursuant to the equity purchase agreement equal to $25 million, (ii) June 30, 2027, (iii) written notice of termination by the Company to Crom Structured, (iv) the registration statement is no longer effective after the initial effective date of the registration statement, or (v) the date that the Company commences a voluntary bankruptcy case, a bankruptcy proceeding is commenced against the Company, a custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors. The purchase price will be calculated as 96% of the VWAP of the Company's common shares on the trading day immediately preceding the respective common shares purchase notice delivery date.

For the three months ended March 31, 2026, no common shares were sold pursuant to the terms of the equity purchase agreement.

*<u>Share Repurchase Program for Common Shares</u>*

 

On February 18, 2026, the Board of Directors of the Company approved a share repurchase program ("2026 Share Repurchase Program"), pursuant to which the Company is authorized to repurchase up to $2 million of its outstanding common shares. The timing and amount of repurchases under the program are determined by the Company's management based on its evaluation of market conditions and other factors. This program has not set termination date and may be suspended or discontinued by at any time.

For the three months ended March 31, 2026, no common shares were repurchased pursuant to the 2026 Share Repurchase Program.

*<u>Reverse Stock Split for Common Shares</u>*

 

On March 4, 2026, the Board of Directors of the Company approved a reverse stock split ("2026 Reverse Stock Split") of the Company's issued and outstanding common shares at a 1-for-20 ratio. The 2026 Reverse Stock Split was effective on April 2, 2026. The Company's authorized number of shares and par value per share of common shares were not affected by the 2026 Reverse Stock Split. References made to share and per share information of common shares disclosed for all periods presented have been retroactively adjusted to reflect the effect of the 2026 Reverse Stock Split.

*<u>Shares Issued and Outstanding</u>*

As of March 31, 2026 and December 31, 2025, there were 1,288,812 and 1,270,991 shares of common shares issued and outstanding, respectively.

As of March 31, 2026 and December 31, 2025, there were 1,017 shares of preferred shares (designated as Series A convertible preferred shares) issued and outstanding.

**NOTE 15 – NET LOSS PER SHARE**

Basic net loss per share is calculated on the basis of weighted average outstanding common shares. Diluted net loss per share is calculated on the basis of basic weighted average outstanding common shares adjusted for the dilutive effect of stock options, RSUs and Series A convertible preferred shares. Potentially dilutive common shares are determined by applying the treasury stock method to the assumed conversion of share repurchase liability to common shares related to the early exercised stock options and unvested RSUs. Potentially dilutive common shares issuable upon conversion of the Series A convertible preferred shares are determined by applying the if-converted method. Potentially dilutive common shares are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive.

The computation of basic and diluted net loss per share for the three months ended March 31, 2026 and 2025 is as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| **Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share – basic** |  |  |
| **Numerator** |  |  |
| Net loss from continuing operations | $(1976715) | $(3070031) |
| Less: net loss from continuing operations attributable to non-controlling interests | (105008) | (50389) |
| Net loss from continuing operations attributable to HeartCore Enterprises, Inc. | (1871707) | (3019642) |
| Dividends accrued on Series A convertible preferred shares | (27968) | - |
| Net loss from continuing operations attributable to HeartCore Enterprises, Inc. common shareholders | (1899675) | (3019642) |
| **Denominator** |  |  |
| Weighted average number of common shares outstanding – basic | 1271631 | 1102702 |
| Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share – basic | $(1.49) | $(2.74) |
| **Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share – diluted** |  |  |
| **Numerator** |  |  |
| Net loss from continuing operations attributable to HeartCore Enterprises, Inc. | $(1871707) | $(3019642) |
| Less: changes in fair value of derivative liability, net of income tax | (626) | - |
| Net loss from continuing operations attributable to HeartCore Enterprises, Inc. – diluted | (1871081) | (3019642) |
| **Denominator** |  |  |
| Weighted average number of common shares outstanding – diluted | 1271631 | 1102702 |
| Net loss from continuing operations attributable to HeartCore Enterprises, Inc. per common share – diluted | $(1.49) | $(2.74) |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| **Loss from discontinued operations per common share – basic and diluted** |  |  |
| **Numerator** |  |  |
| Loss from discontinued operations, net of income tax | $- | $(67350) |
| **Denominator** |  |  |
| Weighted average number of common shares outstanding – basic and diluted | 1271631 | 1102702 |
| Loss from discontinued operations per common share – basic and diluted | $- | $(0.06) |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| **Net loss attributable to HeartCore Enterprises, Inc. per common share – basic** |  |  |
| **Numerator** |  |  |
| Net loss attributable to HeartCore Enterprises, Inc. common shareholders | $(1899675) | $(3086992) |
| **Denominator** |  |  |
| Weighted average number of common shares outstanding – basic | 1271631 | 1102702 |
| Net loss attributable to HeartCore Enterprises, Inc. per common share – basic | $(1.49) | $(2.80) |
| **Net loss attributable to HeartCore Enterprises, Inc. per common share – diluted** |  |  |
| **Numerator** |  |  |
| Net loss attributable to HeartCore Enterprises, Inc. | $(1871707) | $(3086992) |
| Less: changes in fair value of derivative liability, net of income tax | (626) | - |
| Net loss attributable to HeartCore Enterprises, Inc. – diluted | (1871081) | (3086992) |
| **Denominator** |  |  |
| Weighted average number of common shares outstanding – diluted | 1271631 | 1102702 |
| Net loss attributable to HeartCore Enterprises, Inc. per common share – diluted | $(1.49) | $(2.80) |

---

**NOTE 16 – DISCONTINUED OPERATIONS**

On July 24, 2025, in light of the intense competition of the software market in Japan, the Board of Directors of the Company approved to enter into a non-binding letter of intent to sell 100% of the outstanding shares of HeartCore Japan. The Company does not expect to have any continuing involvement in HeartCore Japan subsequent to the closing. The Company determines the sale of HeartCore Japan met the criteria for classification as held for sale. Additionally, the Company determines the sale of HeartCore Japan represents a strategic shift that has a major impact on its operations and financial results. Accordingly, all results of operations of HeartCore Japan have been removed from continuing operations and presented as discontinued operations in the unaudited consolidated statements of operations and comprehensive loss for all periods presented. On October 31, 2025, the sale transaction was closed. The Company entered into a purchase agreement to sell 100% of the outstanding shares of HeartCore Japan to Smith Japan Holdings KK for a cash consideration of approximately $12 million, subject to price adjustment.

The following table summarizes the results of operations from discontinued operations, net of income tax in the unaudited consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025:

---

| | |
|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,**<br>**2025** |
| Revenues | $1493613 |
| Cost of revenues | 937103 |
| Gross profit | 556510 |
| Operating expenses: |  |
| Selling expenses | 138238 |
| General and administrative expenses | 348183 |
| Research and development expenses | 123893 |
| Total operating expenses | 610314 |
| Loss from discontinued operations | (53804) |
| Other income | 3482 |
| Loss from discontinued operations before income tax expense | (50322) |
| Income tax expense | 17028 |
| Loss from discontinued operations, net of income tax | $(67350) |

---

**NOTE 17 – SEGMENT AND GEOGRAPHIC INFORMATION**

*<u>Segment Information</u>*

Operating segments are defined as components of an entity for which discrete financial information is available and is regularly reviewed by the CODM, the CEO of the Company, in making decisions regarding resource allocation and performance assessment. The Company determines its operations constitute a single operating segment and reportable segment in accordance with ASC Topic 280. The CODM assesses financial performance and decides how to allocate resources based on consolidated net loss from continuing operations. Segment assets are reported on the Company's consolidated balance sheets.

The following table summarizes the selected financial information with respect to the Company's single operating segment and reportable segment for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| Revenues | $1245844 | $2093413 |
| Less: |  |  |
| Software related cost of revenues | 1014028 | 1470792 |
| Consulting related cost of revenues | 157771 | 78847 |
| Selling expenses | 42812 | 152922 |
| General and administrative expenses | 1571734 | 1581205 |
| Loss from continuing operations | (1540501) | (1190353) |
| Total other expenses | (418745) | (1840070) |
| Loss from continuing operations before income tax expense | (1959246) | (3030423) |
| Income tax expense | 17469 | 39608 |
| Net loss from continuing operations | $(1976715) | $(3070031) |

---

*<u>Geographic Information</u>*

The following table summarizes the breakdown of revenues by geography for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** | **2025** |
| United States | $929942 | $1736018 |
| Japan | 25747 | 245543 |
| International | 290155 | 111852 |
| Total revenues | $1245844 | $2093413 |

---

The following table summarizes the breakdown of long-lived assets by geography as of March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| United States | $34442 | $27792 |
| Japan | 743376 | 292451 |
| International | 7823 | 795 |
| Total long-lived assets | $785641 | $321038 |

---

**NOTE 18 – SUBSEQUENT EVENTS**

On April 1, 2026, the Company converted partial of the warrants it received from a customer as noncash consideration from consulting services into marketable securities.

On April 9, 2026, the Company sold marketable securities for proceeds of approximately $202,000.

During the subsequent period, there were 400 shares of Series A convertible preferred shares converted into 152,753 shares of common shares.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), provide a safe harbor for forward-looking statements made by us or on our behalf. We and our representatives may from time to time make written or oral statements that are "forward-looking," including statements contained in this Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission ("SEC") and in our reports and presentations to stockholders or potential stockholders. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties can be found in Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as the same may be updated from time to time, including in Part II, Item 1A, "Risk Factors," of this Quarterly Report on Form 10-Q.*

*Although we believe the expectations reflected in our forward-looking statements are based upon reasonable assumptions, it is not possible to foresee or identify all factors that could have a material effect on the future financial performance of the Company. The forward-looking statements in this Quarterly Report on Form 10-Q are made on the basis of management's assumptions and analyses, as of the time the statements are made, in light of their experience and perception of historical conditions, expected future developments and other factors believed to be appropriate under the circumstances.*

*Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q and the information incorporated by reference in this Quarterly Report on Form 10-Q to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.*

*Unless the context otherwise requires, references herein to "we," "us" or the "Company" refer to HeartCore Enterprises, Inc. ("HeartCore USA") and its consolidated subsidiaries, including HeartCore Financial, Inc. and its branch office in Japan, Higgs Field Co., Ltd., HeartCore Luvina Vietnam Company Limited ("HeartCore Luvina"), and Sigmaways, Inc. ("Sigmaways") and its subsidiaries.*

**Business Overview**

In 2022, HeartCore USA started the Go IPO business, which supports Japanese companies listing on The Nasdaq Stock Market ("Nasdaq") and the New York Stock Exchange ("NYSE") in the United States. As of March 31, 2026, we have entered into consulting agreements with 16 companies to assist them in their IPO process, whereby we are entitled to receive from each company a consulting fee that ranges from $380,000 to $900,000 and warrants or stock acquisition rights to purchase 1% to 4% of the fully-diluted share capital of such companies that is exercisable on certain dates at an exercise price of $0.01 or JPY1 per share.

Prior to November 2025, we were also a leading software development company based in Tokyo, Japan. We provided software through two business units. The first business unit, our CX division, included a customer experience management business (the "CXM Platform"). The second business unit, our DX division, was a digital transformation business which provided customers with robotics process automation, process mining and task mining to accelerate the digital transformation of enterprises. In 2025, we made the strategic decision to sell our software business assets in Japan and to concentrate our efforts on our Go IPO consulting business. On October 31, 2025, the Company entered into a Purchase Agreement (the "HeartCore Japan Agreement") with Smith Japan Holdings KK ("Smith Japan"), pursuant to which the Company agreed to sell to Smith Japan, and Smith Japan agreed to purchase (the "HeartCore Japan Sale"), all of the outstanding equity interests of HeartCore Co., Ltd., a then-wholly owned subsidiary of the Company ("HeartCore Japan"). The HeartCore Japan Sale closed on October 31, 2025.

*Go IPO Consulting Services*

Since February 2022, we have been offering Go IPO consulting services, which include the following (collectively, the "Services"):

● Assisting with introductions to law firms, underwriters and auditing firms, in order that clients can make their selections, at their sole discretion;

● Assisting in the preparation of documentation for internal controls required for an initial public offering and simultaneous listing on the Nasdaq, the NYSE or the NYSE American;

● Providing support services to remove problematic accounting accounts upon listing support;

● Translation of requested documents into English;

● Attend and, if requested by the other party, lead, meetings of management and employees;

● Provide support services related to the Nasdaq, the NYSE or the NYSE American listing;

● Conversion of accounting data from Japanese standards to accounting principles generally accepted in the U.S. ("U.S. GAAP");

● Assist in the preparation of S-1 or F-1 filings;

● Creation of English web page; and

● Preparing an investor presentation/deck and executive summary of the operations.

In providing the Services, we do not provide investment advice regarding the value of securities, nor do we engage in the solicitation of investors or the negotiation of securities transactions. We do not provide accounting or legal advice, and we do not act as an investment advisor or broker-dealer.

Pursuant to the terms of the consulting agreements with our clients, the parties agree that we will not provide the following services, among others: negotiation of the sale of the issuers' securities; participation in discussions between the issuers and potential investors; assisting in structuring any transactions involving the sale of the issuers' securities; pre-screening of potential investors; due diligence activities; and providing advice relating to valuation of or financial advisability of any investments in the issuers. Additionally, we do not take part in the selection of, or negotiation of terms with, law firms, underwriters or audit firms. Such selection and negotiation is the sole responsibility of the client.

Pursuant to the terms of the consulting agreements with the issuers, the issuers agree to compensate us as follows in return for the provision of Services during the initial term of the consulting agreements:

● A cash fee payable in installment payments; and

● Issuance by issuers to us of warrants or stock acquisition rights to acquire a number of shares of capital stock of the issuer, to initially be equal to a designated percentage of the fully diluted share capital of the issuer, subject to adjustment as set forth in the warrants or stock acquisition rights.

**Recent Developments**

*Share Repurchase Program*

During the first quarter of 2026, the Company's Board of Directors (the "Board") authorized a share repurchase program, pursuant to which the Company may repurchase up to $2.0 million of its outstanding shares of common stock. The Board authorized the Company to purchase its common stock from time to time on a discretionary basis through open market purchases, privately negotiated transactions or other means, including trading plans intended to qualify under Rule 10b5-1 of the Exchange Act, in accordance with applicable federal securities laws and other applicable legal requirements. The Company expects to fund these repurchases through existing cash balances. Decisions regarding the amount and the timing of purchases under the program will be influenced by the Company's cash on hand, cash flows from operations, general market conditions and other factors, and the program may be modified, suspended or discontinued at any time. The Company is not obligated to acquire any particular amount of its common stock. This program has no set termination date.

*Bylaws Amendment*

On March 24, 2026, the Board adopted an amendment (the "Amendment") to the Company's bylaws (the "Bylaws").

Prior to adoption of the Amendment, the second sentence of Section 7.4 of the Bylaws provided that "[i]f any action is brought by any party against another party, relating to or arising out of [the] Bylaws, or the enforcement hereof, the prevailing party shall be entitled to recover from the other party reasonable attorneys' fees, costs and expenses incurred in connection with the prosecution or defense of such action", and Section 7.5 of the Bylaws provided (and continues to provide following adoption of the Amendment) that "[a]ll powers, duties and responsibilities provided for in [the] Bylaws, whether or not explicitly so qualified, are qualified by the provisions of the [Company's certificate of incorporation] and applicable law."

The Amendment had the effect of amending and restating the second sentence of Section 7.4 of the Bylaws to read as follows: "If any action is brought by any party against another party, relating to or arising out of these Bylaws, or the enforcement hereof, the prevailing party shall be entitled to recover from the other party reasonable attorneys' fees, costs and expenses incurred in connection with the prosecution or defense of such action, provided that the provisions of this sentence shall not apply with respect to "internal corporate claims" as defined in Section 115 of the DGCL or in connection with any other claim that a stockholder, acting in its capacity as a stockholder or in the right of the Corporation, has brought in an action, suit or proceeding."

The Amendment was intended to clarify that, consistent with Section 7.5 of the Bylaws and the provisions of the Delaware General Corporation Law, including Section 109(b) thereof, the Bylaws do not contain any provision that would impose liability on a stockholder for the attorneys' fees or expenses of the Company or any other party in connection with an internal corporate claim, or in connection with any other claim that a stockholder, acting in its capacity as a stockholder or in the right of the Company, has brought in an action, suit or proceeding.

*Reverse Stock Split*

As previously disclosed, on June 30, 2025, the Company's stockholders approved an amendment to the Company's certificate of incorporation, as amended (the "Certificate of Incorporation"), to effectuate a reverse stock split of the Company's outstanding shares of common stock, at a ratio of no less than 1-for-2 and no more than 1-for-30, with such ratio to be determined at the sole discretion of the Board. On March 4, 2026, the Board approved a 1-for-20 reverse stock split of the Company's issued and outstanding common stock (the "Reverse Split"). Subsequently, the Company filed a certificate of amendment (the "Certificate of Amendment") to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effectuate the Reverse Split. The Certificate of Amendment was effective for state law purposes at 4:00 p.m. Eastern Time on April 2, 2026 (the "Effective Time"), after the close of trading on the Nasdaq Capital Market ("Nasdaq"), such that the Company's common stock began trading on Nasdaq at market open on April 6, 2026, on a post-Reverse Split basis.

As of the Effective Time, issued and outstanding shares of the Company's common stock were automatically reclassified such that each 20 shares of pre-Reverse Split common stock became one share of common stock, with any fractional shares of common stock resulting being rounded up to the nearest whole share of common stock. The authorized number of shares, and par value per share, of the Company's common stock were not affected by the Reverse Split.

*Compliance with Nasdaq Minimum Bid Price Requirement*

As previously disclosed, on May 6, 2025, the Company received written notice (the "Bid Price Notice") from the Nasdaq Staff indicating that the Company was not in compliance with the Minimum Bid Price Requirement. The notification of noncompliance had no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market. The Bid Price Notice indicated that the Company was provided 180 calendar days, or until November 3, 2025, in which to regain compliance. On November 4, 2025, the Nasdaq Staff notified the Company of its determination that the Company was eligible for an additional 180-day period, or until May 1, 2026, to regain compliance with the Minimum Bid Price Requirement.

On April 20, 2026, the Company received written notice from the Nasdaq Staff that the Company has regained compliance with the Minimum Bid Price Requirement and the matter has now been closed. Accordingly, the Company's common stock continues to be listed and traded on the Nasdaq Capital Market.

**Financial Overview**

For the three months ended March 31, 2026 and 2025, we generated revenues of $1,245,844 and $2,093,413, respectively, and reported a net loss from continuing operations of $1,976,715 and $3,070,031, respectively, and had net cash flows used in operating activities of continuing operations of $1,153,590 and $1,691,459, respectively. As noted in our unaudited consolidated financial statements, as of March 31, 2026, we had an accumulated deficit of $15,627,241.

**<u>Results of Operations</u>**

**Comparison of Results of Operations for the Three Months Ended March 31, 2026 and 2025**

The following table summarizes our operating results as reflected in our unaudited consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025, respectively, and provides information regarding the dollar and percentage increase (or decrease) during such periods.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** |
|  | **2026** | **2026** | **2025** | **2025** | **Variance** | **Variance** |
|  |<br>**Amount** | **% of**<br>**Revenues** |<br>**Amount** | **% of**<br>**Revenues** |<br>**Amount** |<br>**%** |
| **Revenues** | $1245844 | 100.0% | $2093413 | 100.0% | $(847569) | -40.5% |
| **Cost of revenues** | 1171799 | 94.1% | 1549639 | 74.0% | (377840) | -24.4% |
| **Gross profit** | 74045 | 5.9% | 543774 | 26.0% | (469729) | -86.4% |
| **Operating expenses:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling expenses | 42812 | 3.4% | 152922 | 7.3% | (110110) | -72.0% |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 1571734 | 126.2% | 1581205 | 75.5% | (9471) | -0.6% |
| **Total operating expenses** | 1614546 | 129.6% | 1734127 | 82.8% | (119581) | -6.9% |
| **Loss from continuing operations** | (1540501) | -123.7% | (1190353) | -56.8% | 350148 | 29.4% |
| **Other expenses** | (418745) | -33.6% | (1840070) | -87.9% | (1421325) | -77.2% |
| **Loss from continuing operations before income tax expense** | (1959246) | -157.3% | (3030423) | -144.7% | (1071177) | -35.3% |
| **Income tax expense** | 17469 | 1.4% | 39608 | 1.9% | (22139) | -55.9% |
| **Net loss from continuing operations** | (1976715) | -158.7% | (3070031) | -146.6% | (1093316) | -35.6% |
| **Loss from discontinued operations, net of income tax** | - | 0.0% | (67350) | -3.2% | (67350) | -100.0% |
| **Net loss** | (1976715) | -158.7% | (3137381) | -149.8% | (1160666) | -37.0% |
| &nbsp;&nbsp;&nbsp;Less: net loss attributable to non-controlling interests | (105008) | -8.4% | (50389) | -2.4% | 54619 | 108.4% |
| **Net loss attributable to HeartCore Enterprises, Inc.** | (1871707) | -150.3% | (3086992) | -147.4% | (1215285) | -39.4% |
| &nbsp;&nbsp;&nbsp;Dividends accrued on Series A convertible preferred shares | (27968) | -2.2% | - | 0.0% | 27968 | 100.0% |
| **Net loss attributable to HeartCore Enterprises, Inc. common shareholders** | $(1899675) | -152.5% | $(3086992) | -147.4% | $(1187317) | -38.5% |

---

*Revenues*

Our revenues decreased by $847,569, or 40.5%, to $1,245,844 for the three months ended March 31, 2026 from $2,093,413 for the three months ended March 31, 2025, mainly attributable to a decreased revenue of $827,435 from customized software development and services in connection with the intense competition in the U.S. software market.

*Cost of Revenues*

Our cost of revenues decreased by $377,840, or 24.4%, to $1,171,799 for the three months ended March 31, 2026 from $1,549,639 for the three months ended March 31, 2025, mainly attributable to a decrease of $539,614 in the cost of customized software development and services, which was in light of the decrease in sales of respective revenues.

*Gross Profit*

Our gross profit decreased by $469,729, or 86.4%, to $74,045 for the three months ended March 31, 2026 from $543,774 for the three months ended March 31, 2025, mainly attributable to (i) a decrease of $298,720 in gross profit from our Go IPO consulting services, as we as spent more efforts and resources and incurred more outsourcing fees for Go IPO consulting services to enhance our Go IPO consulting customers experience with us, resulted in lower gross profit for our Go IPO consulting services; (ii) a decrease of $287,821 in customized software development and services in light of the decrease in customized software development and services revenues and the increase in respective cost in connection with the increasing subcontracting fees for outsourced software engineers due to the salary level increase in the overall software market; and offset by (iii) an increase of $116,812 in software development and other services provided by HeartCore Luvina due to the increase in software development and other services revenues and decrease in respective cost due to the cost control policy we implemented.

For the reasons discussed above, our overall gross profit margin decreased by 20.1% to 5.9% for the three months ended March 31, 2026 from 26.0% for the three months ended March 31, 2025.

*Selling Expenses*

Our selling expenses decreased by $110,110, or 72.0%, to $42,812 for the three months ended March 31, 2026 from $152,922 for the three months ended March 31, 2025, primarily attributable to a decrease of $95,668 in advertising and referral expenses, as we reduced certain marketing and referral activities and cancelled promotion campaigns with lower advertising performance.

*General and Administrative Expenses*

Our general and administrative expenses were $1,571,734 and $1,581,205 for the three months ended March 31, 2026 and 2025, respectively, and remained stable across periods with minor decrease.

*Other Expenses, Net*

Our other income (expenses) includes changes in fair value of investments in marketable securities, changes in fair value of investment in warrants, changes in fair value of derivative liability, interest income generated from bank deposits, interest expenses for loans, other income, and other expenses. Total other expenses, net decreased by $1,421,325, or 77.2%, to $418,745 for the three months ended March 31, 2026, from total other expenses, net of $1,840,070 for the three months ended March 31, 2025, primarily attributable to a decrease of $1,485,667 in changes of fair value of investments in marketable securities due to fair value measurement across periods.

*Income Tax Expense*

Our income tax expense were minimal, which were $17,496 and $39,608 for the three months ended March 31, 2026 and 2025, respectively, as we incurred pre-tax loss positions across periods.

*Loss from Discontinued Operations, Net of Income Tax*

On July 24, 2025, the Board of Directors of the Company approved to enter into a non-binding letter of intent to sell 100% of the outstanding shares of HeartCore Co., Ltd. On October 31, 2025, the Company entered into the HeartCore Japan Agreement with Smith Japan in relation to the sale of HeartCore Co., Ltd. The results of operations of HeartCore Co., Ltd. are reported as discontinued operations for all periods presented, as the sale of HeartCore Co., Ltd. represents a strategic shift that has a major impact on the Company's operations and financial results. The HeartCore Co., Ltd. sale closed on October 31, 2025. We reported a loss from discontinued operations, net of income tax of $67,350 for the three months ended March 31, 2025.

*Net Loss Attributable to Non-controlling Interests*

We owned a 51% equity interest of Sigmaways and its subsidiaries and a 51% equity interest of HeartCore Luvina. Accordingly, we recorded net loss attributable to non-controlling interests of $105,008 and $50,389 for the three months ended March 31, 2026 and 2025, respectively.

*Dividends Accrued on Series A Convertible Preferred Shares*

On June 30, 2025, we issued 2,000 shares of Series A convertible preferred shares, which were granted a cumulative dividend of 10% per annum. Accordingly, we recorded dividends accrued on Series A convertible preferred shares of $27,968 and nil for the three months ended March 31, 2026 and 2025, respectively.

*Net Loss Attributable to HeartCore Enterprises, Inc. Common Shareholders*

As a result of the foregoing, we reported a net loss attributable to HeartCore Enterprises, Inc. common shareholders of $1,899,675 for the three months ended March 31, 2026, representing a $1,187,317, or 38.5%, decrease from a net loss attributable to HeartCore Enterprises, Inc. common shareholders of $3,086,992 for the three months ended March 31, 2025.

**Liquidity and Capital Resources**

As of March 31, 2026, we had $774,033 in cash and cash equivalents, as compared to $1,985,962 as of December 31, 2025. We also had $572,547 in accounts receivable as of March 31, 2026. Our accounts receivable primarily include the balance due from customers for our customized software development and services accepted by customers.

As of March 31, 2026, our working capital was $1,010,549. In assessing our liquidity, management monitors and analyzes our cash, our ability to generate sufficient revenues in the future, and our operating and capital expenditure commitments.

The following table sets forth a summary of our cash flows for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months <br> Ended March 31,** | **For the Three Months <br> Ended March 31,** |
|  | **2026** | **2025** |
| Net cash flows used in operating activities of continuing operations | $(1153590) | $(1691459) |
| Net cash flows provided by (used in) investing activities of continuing operations | (954) | 462763 |
| Net cash flows provided by (used in) financing activities of continuing operations | (53513) | 162855 |
| Net cash flows used in discontinued operations |  | (318949) |
| Effect of exchange rate changes | (3872) | 2685 |
| Net change in cash and cash equivalents | (1211929) | (1382105) |
| Cash and cash equivalents, beginning of the period | 1985962 | 2121089 |
| Cash and cash equivalents, end of the period | $774033 | $738984 |

---

*Cash Flows from Operating Activities of Continuing Operations*

Net cash flows used in operating activities of continuing operations was $1,153,590 for the three months ended March 31, 2026, primarily consisting of the following:

● Net loss from continuing operations of $1,976,715 for the three months ended March 31, 2026.

● Offset by loss of $295,997 on fair value changes in investments in marketable securities due to fair value measurement.

● Offset by a decrease of $135,238 in accounts receivable in line with the decrease in revenues.

● Offset by an increase of $154,736 in accrued payroll and other employee costs, primarily resulting from Sigmaways's payroll delayed arrangement in response to its sales slowdown.

*Cash Flows from Investing Activities of Continuing Operations*

Net cash flows used in investing activities of continuing operations amounted to $954 for the three months ended March 31, 2026, for purchase of property and equipment.

*Cash Flows from Financing Activities of Continuing Operations*

Net cash flows used in financing activities of continuing operations amounted to $53,513 for the three months ended March 31, 2026, primarily consisting of $23,657 for repayment of insurance premium financing, $12,382 for repayment of long-term debts, and $11,474 for net repayment of factoring arrangement.

**Contractual Obligations**

*Lease Commitment*

The Company has entered into operating leases for office space. As of March 31, 2026, the future maturity of lease liabilities is as follows:

---

| | |
|:---|:---|
| <br>**Year Ended December 31,** | **Operating**<br>**Leases** |
| Remaining of 2026 | $238721 |
| 2027 | 283420 |
| 2028 |  |
| 2029 |  |
| 2030 |  |
| Thereafter | - |
| Total lease payments | 522141 |
| Less: imputed interest | (2478) |
| Total lease liabilities | 519663 |
| Less: current portion | (308119) |
| Non-current lease liabilities | $211544 |

---

*Debts*

The Company's debts included long-term debts borrowed from a bank and a financial institution. As of March 31, 2026, future minimum principal payments for long-term debts were as follows:

---

| | |
|:---|:---|
| **Year Ended December 31,** | **Principal Payment** |
| Remaining of 2026 | $38216 |
| 2027 | 55325 |
| 2028 | 60471 |
| 2029 | 27857 |
| 2030 | 9973 |
| Thereafter | 294750 |
| Total | $486592 |

---

**Off-Balance Sheet Arrangements**

We did not have any off-balance sheet arrangements as of March 31, 2026.

**Critical Accounting Policies and Estimates**

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited consolidated financial statements. These unaudited consolidated financial statements are prepared in accordance with the generally accepted accounting principles in the United States ("U.S. GAAP"), which requires us to make estimates and assumptions that affect the reported amounts of our assets and liabilities and revenues and expenses, to disclose contingent assets and liabilities on the date of the unaudited consolidated financial statements, and to disclose the reported amounts of revenues and expenses incurred during the financial reporting period. We continue to evaluate the estimates and assumptions that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from those estimates. We believe there are no critical accounting policies and estimates for the three months ended March 31, 2026.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable.

**ITEM 4. CONTROLS AND PROCEDURES**

Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2026. Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2026, our disclosure controls and procedures were not effective, for the same reason as previously disclosed under Item 9A. "Controls and Procedures" in our Annual Report on Form 10-K for our fiscal year ended December 31, 2025, as filed with the SEC on March 31, 2026, as the same may be amended from time to time.

*Changes in Internal Control Over Financial Reporting*

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

From time to time, we are involved in various claims and legal actions arising in the ordinary course of business. To the knowledge of our management, there are no legal proceedings currently pending against us which we believe would have a material effect on our business, financial position or results of operations and, to the best of our knowledge, there are no such legal proceedings contemplated or threatened.

**ITEM 1A. RISK FACTORS**

As a smaller reporting company, we are not required to disclose material changes to the risk factors that were contained in our Annual Report on Form 10-K for the year ended December 31, 2025, as the same may be updated from time to time.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

There have been no defaults in any material payments during the covered period.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5. OTHER INFORMATION**

(a) None.

(b) There have been no material changes to the procedures by which security holders may recommend nominees to our Board of Directors since we last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K.

(c) During the quarter ended March 31, 2026, no HeartCore USA director or officer adopted or terminated a contract, instruction or written plan for the purchase or sale of HeartCore USA securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and/or a non-Rule 10b5-1 trading arrangement.

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description of Document** |
| 3.1 | [Amendment to Bylaws of the registrant, dated March 24, 2026 (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on March 27, 2026).](https://www.sec.gov/Archives/edgar/data/1892322/000149315226013198/ex3-1.htm) |
| 3.2 | [Certificate of Amendment to the Certificate of Incorporation, as amended, of the issuer, effective April 2, 2026 (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on April 6, 2026).](https://www.sec.gov/Archives/edgar/data/1892322/000149315226015297/ex3-1.htm) |
| 31.1\* | [Rule 13a-14(a) Certification of Principal Executive Officer.](ex31-1.htm) |
| 31.2\* | [Rule 13a-14(a) Certification of Principal Financial Officer.](ex31-2.htm) |
| 32.1\*\* | [Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Principal Executive Officer and Principal Financial Officer.](ex32-1.htm) |
| 101.INS\* | Inline XBRL Instance Document |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase |
| 101.LAB\* | Inline XBRL Taxonomy Extension Labels Linkbase |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase |
| 104\* | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Filed herewith. <br> \*\* Furnished herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **HEARTCORE ENTERPRISES, INC.** | **HEARTCORE ENTERPRISES, INC.** |
| Dated: May 15, 2026 | By: | */s/ Sumitaka Yamamoto* |
|  |  | Sumitaka Yamamoto |
|  |  | Chief Executive Officer and President (principal executive officer) |
| Dated: May 15, 2026 | By: | */s/ Qizhi Gao* |
|  |  | Qizhi Gao |
|  |  | Chief Financial Officer (principal financial officer and principal accounting officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**<u>CERTIFICATIONS</u>**

I, Sumitaka Yamamoto, certify that:

1. I
 have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 of HeartCore Enterprises, Inc.; and

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report; and

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
 this report; and

4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
 within those entities, particularly during the period in which this report is being prepared;

b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of the annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The
 registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
 financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or
 persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 15, 2026 | By: | */s/ Sumitaka Yamamoto* |
|  |  | Sumitaka Yamamoto |
|  |  | Chief Executive Officer and President (principal executive officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**<u>CERTIFICATIONS</u>**

I, Qizhi Gao, certify that:

1. I
 have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 of HeartCore Enterprises, Inc.; and

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report; and

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
 this report; and

4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
 within those entities, particularly during the period in which this report is being prepared;

b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of the annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The
 registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
 financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or
 persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 15, 2026 | By: | */s/ Qizhi Gao* |
|  |  | Qizhi Gao |
|  |  | Chief Financial Officer (principal financial officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of HeartCore Enterprises, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Sumitaka Yamamoto, Chief Executive Officer and President of the Company, and I, Qizhi Gao, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | |
|:---|:---|
| Date: May 15, 2026 | */s/ Sumitaka Yamamoto* |
|  | Sumitaka Yamamoto |
|  | Chief Executive Officer and President (principal executive officer) |
| Date: May 15, 2026 | */s/ Qizhi Gao* |
|  | Qizhi Gao |
|  | Chief Financial Officer (principal financial officer) |

---

*This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.*